|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Six Minute Walk Test to assess functional capacity in chronic liver disease patients显示文摘AIM: To examine the utility of Six Minute Walk Test (6MWT) in patients with chronic liver disease (CLD). METHODS: Two hundred and fifty subjects between the ages of 18 and 80 (mean 47) years performed 6MWT and the Six Minute Walk Distance (6MWD) was measured. RESULTS: The subjects were categorized into four groups. Group A (n = 45) healthy subjects (control); group B (n = 49) chronic hepatitis B patients; group C (n = 54) chronic hepatitis C patients; group D (n = 98) liver cirrhosis patients. The four groups differed in terms of 6MWDs (P < 0.001). The longest distance walked was 421 ± 47 m by group A, then group B (390 ± 53 m), group C (357 ± 72 m) and group D (306 ± 111 m). The 6MWD correlated with age (r = -0.482, P < 0.01), hemoglobin (r = +0.373, P < 0.001) and albumin (r = +0.311, P < 0.001) levels. The Child-Pugh classification was negatively correlated with the 6MWD in cirrhosis (group D) patients (r = -0.328, P < 0.01). At the end of a 12 mo follow-up period, 15 of the 98 cirrhosis patients had died from disease complications. The 6MWD for the surviving cirrhotic patients was longer than for non-survivors (317 ± 101 vs 245 ± 145 m, P = 0.021; 95% CI 11-132). The 6MWD was found to be an independent predictor of survival (P = 0.024). CONCLUSION: 6MWT is a useful tool for assessing physical function in CLD patients. We suggest that 6MWD may serve as a prognostic indicator in patients with liver cirrhosis. | Hatem F Alameri Faisal M Sanai Manal Al Dukhayil Nahla A Azzam Khalid A Al-Swat Ahmad S Hersi Ayman A Abdo | 2007 | World Journal of Gastroenterology2007，13，29： | 5 |
| 2 | Drainage vs. non-drainage after cholecystectomy for acute cholecystitis:a retrospective study显示文摘Many surgeons practice prophylactic drainage after cholecystectomy without reliable evidence,this study was conducted to answer the question whether to drain or not to drain after cholecystectomy for acute calculous cholecystitis.A retrospective review of all patients who had cholecystectomy for acute cholecystitis in Aseer Central Hospital,Abha,Saudi Arabia,was conducted from April 2010 to April 2012.Data were extracted from hospital case files.Preoperative data included clinical presentation,routine investigations and liver function tests.Operative data included excessive adhesions,bleeding,bile leak,and drain insertion.Complicated cases such as pericholecystic collections,mucocele and empyema were also reported.Patients who needed therapeutic drainage were excluded.Postoperative data included hospital stay,volume of drained fluid,time of drain removal,and drain site problems.The study included 103 patients allocated into two groups;group A(n = 38) for patients with operative drain insertion and group B(n = 65) for patients without drain insertion.The number of patients with preoperative diagnosis of acute non-complicated cholecystitis was significantly greater in group B(80%) than group A(36.8%)(P < 0.001).Operative time was significantly longer in group A.All patients who were converted from laparoscopic to open cholecystectomy were in group A.Multivariate analysis revealed that hospital stay was significantly(P < 0.001) longer in patients with preoperative complications.There was no added benefit for prophylactic drain insertion after cholecystectomy for acute calculous cholecystitis in non-complicated or in complicated cases. | Mohammed A Bawahab Walid M Abd El Maksoud Saeed A Alsareii Fahad S Al Amri Hala F Ali Abdul Rahman Nimeri Abdul Rahman M Al Amri Adel A Assiri Mohammed I Abdul Aziz | 2014 | The Journal of Biomedical Research2014，28，3： | 3 |
| 3 | Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage显示文摘AIM: To evaluate pegylated interferon alpha2a (PegIFN- α2a) in Egyptian patients with HCV genotype 4, and the impact of pretreatment viral load, co-existent bilharziasis and histological liver changes on response rate. METHODS: A total of 73 na?ve patients (61 with history of bilharziasis) with compensated chronic HCV genotype 4 were enrolled into: group A (38 patients) who received 180 mg PegIFN-alpha2a subcutaneously once weekly for a year and group B (35 patients) received IFN alpha-2a 3 MU 3 times weekly. Ribavirin was added to each regimen at a dose of 1200 mg. Patients were followed for 72 wk and sustained response was assessed. RESULTS: Significant improvement in both end of treatment response (ETR) (P < 0.002) and sustained response (SR) (P < 0.05) was noted with pegylated interferon, where ETR was achieved in 29 (76.3%) and 14 patients (40%) in both groups respectively, and 25 patients in group A (65.8%) and 9 (25.7%) in group B could retain negative viraemia by the end of follow up period. Sustained virological response (SVR) showed a significant negative correlation with age and positive correlation with pretreatment inflammation in patients receiving PegIFN. Viral clearance after 3 mo of therapy was associated with high incidence of ETR and SR (P < 0.001), but without significant difference between both forms of interferon. Significant improvement in response was achieved in patients with high grade fibrosis (grade 3 and 4) with PegIFN-α2a, where SR was seen in 5 out of 13 patients in group A, but none in group B. There was no significant difference in response betweenbilharzial and non-bilharzial patients in both groups. In terms of safety and tolerability, neutropenia was the predominant side effect; both drugs were comparable. CONCLUSION: PegIFN-α2a combined with ribavirin results in improvement in sustained response in HCV genotype 4, irrespective of history of bilharzial infestation. | MF Derbala SR Al Kaabi NZ El Dweik F Pasic MT Butt R Yakoob A Al-Marri AM Amer N Morad A Bener | 2006 | World Journal of Gastroenterology2006，12，35： | 3 |
| 4 | Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors显示文摘AIM:To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors(PNETs)and provide consensus treatment recommendations.METHODS:Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs,angiogenesis inhibitors,inhibitors of mammalian target of rapamycinand cytotoxic agents.At this time,there is little data to guide treatment selection and sequence.We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations.Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process.After studying the literature,a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale.Ratings were done both before and after an extended discussion of the evidence.Quantitative measurements of agreement were made and consensus statements developed from the second round ratings.RESULTS:Specialties represented were medical and surgical oncology,interventional radiology,and gastroenterology.Panelists had practiced for a mean of15.5 years(range:6-33).Among 202 rated scenarios,disagreement decreased from 13.2%(26 scenarios)before the face-to-face discussion of evidence to 1%(2)after.In the final ratings,46.5%(94 scenarios)were rated inappropriate,21.8%(44)were uncertain,and30.7%(62)were appropriate.Consensus statements from the scenarios included:(1)it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic;(2)it is appropriate to use everolimus,sunitinib,or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors;and(3)beyond first line,these same agents can be used.In patients with uncontrolled secretory symptoms,octreotide LAR doses can be titrated up to 60 mg every4 wk or up to 40 mg every 3 or 4 wk.CONCLUSION:Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs. | Jonathan R Strosberg George A Fisher Al B Benson Lowell B Anthony Bulent Arslan John F Gibbs Edward Greeno Renuka V Iyer Michelle K Kim William J Maples Philip A Philip Edward M Wolin Dasha Cherepanov Michael S Broder | 2015 | World Journal of Gastroenterology2015，21，8： | 2 |
| 5 | Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients显示文摘AIM: To assess the efficacy and safety of combinedpegylated interferon and ribavirin therapy in hepatitis C virus (HCV) infection in renal transplant recipients. METHODS: This is a retrospective chart review of post renal transplant patients who were positive for anti-HCV and HCV-RNA, and who have received treatment with combination of pegylated interferon and ribavirin between October 2003 and December 2008. Only patients with stable graft function and absence of evidence of cirrhosis and who received the therapy for continuous 48 wk were included. Nineteen patients (13 male and 6 female) were identified and included. The patient's complete blood count, liver and kidney prof ile, and cal- culated glomerular f iltration rate (GFR) were monitored every 6-8 wk while on treatment. HCV-RNA was tested at 12 wk for early virological response, at 48 wk for end of treatment response (ETR), and then retested at 24, and 48 wk after completion of therapy for sustained virological response (SVR). Liver biopsies were obtained before treatment from all patients and graft kidney biopsies were performed as required. RESULTS: Of the entire cohort, 9 patients (47.4%) showed an ETR and 8 had SVR (42.1%). Of the 8 patients with abnormal alanine aminotransferase (ALT) levels at baseline, 78.9% had their ALT normalized (including the virological non responders). ALT was normal in all responders at the end of therapy and at 24 wk post therapy (100%). Only one patient (5.3%) developed an increase in creatinine and decline in GFR from baseline towards the end of treatment. This patient's kidney biopsy revealed borderline rejection. There was no impact on response by HCV-genotype, initial HCV RNA load, age or sex of the patient or duration post transplant before commencement of therapy. All patients tolerated treatment in the same way as non-transplant with no unusual or increased occurrence of side effects. CONCLUSION: The combination of pegylated interferon and ribavirin is effective in suppressing HCV-RNA,with a low risk of graft rejection or failure in HCV infected renal transplant recipients. | Abdulrahman A Aljumah Mohamed A Saeed Ahmed I Al Flaiw Ibrahim H Al Traif Abduljaleel M Al Alwan Salem H Al Qurashi Ghormallah A Al Ghamdi Fayez F Al Hejaili Mohammed A Al Balwi Abdulla A Al Sayyari | 2012 | World Journal of Gastroenterology2012，18，1： | 2 |
| 6 | Human cytomegalovirus: detection of congenital and perinatal infection in Argentina 显示文摘 | Distefano AL Alonso A Martin F | 2004 | BMC Pediatr2004，23，1： | 1 |
| 7 | Synergy between Zwittermicin A and Bacillus thuringiensis subsp, leurstaki against gypsy moth (Lepidoptera : Lymantriidae)显示文摘 | Broderick N A Goodman R M Raffa K F el al | 2000 | Environmental Entomology2000，29，： | 1 |
| 8 | Synchronous liver resection and cryotherapy for colorectal metastases : survival analysis 显示文摘 | Brooks A J Wang F Alfredson M d al | 2005 | Surgeon2005，3，4： | 1 |
| 9 | Molecular epidemiology of Staphylococcus haemolyticus strains isolated in an albanian hospital 显示文摘 | Renaud F Etienne J Bertrand A el al | 1991 | J Clin Microbiol1991，29，7： | 1 |
| 10 | Bioelectrochemical Monitoring of Phenols and Aromatic Amines in Flow Injection Using Novel Plant Peroxidases 显示文摘 | Munteanu F D Lindgren A Emneus J ea al | 1998 | Anal Chem1998，70，13： | 1 |
| 11 | Storage of light in atomic vapor显示文摘 | PHILLIPS D F FLEISCHHAUER A MAIR A ct al | 2001 | PHYS REV LETT2001，86，： | 1 |
| 12 | The effect of cerebral monitoring on recovery after general anesthesia: a comparison of the auditory evoked potential and bispectral index devices with standard clinical practice 显示文摘 | RECART A GASANOVA I WHITE P F ct al | 2003 | AnesthAnalg2003，97，6： | 1 |
| 13 | The role of angular momentum compensation显示文摘 | Stanciu C D Kimel A V Hansteen F et aL Ultrafast spin dynamics across compensation points in ferrimagnetic GdFeCo | 2006 | Phys Rev B2006，73，22： | 1 |
| 14 | A high-power, variable repetition rate, picosecond optical parametric oscillator pumped by anamplified gain-switched diode显示文摘 | F Kienle K K Chen S A lam et aL | 2010 | Opt Express2010，18，8： | 1 |
| 15 | Compliance of Jordan- Jan dentists with infection control strategies 显示文摘 | Al Negrish A Al Momani AS Al Sharafat F | 2008 | Int Dent J2008，58，5： | 1 |
| 16 | Autotrophic nitrogenremoval in a membrane-aerated biofilm reactor under continuousaeration : a demonstration 显示文摘 | Gilmore K R Terada A Smets B F ef al | 2013 | Environmental EngineeringScience2013，30，1： | 1 |
| 17 | Association of a lysine-232/alanine polymorphism in a bovine gene encoding acyl-CoA:diacylglycerol acyltransferase(DGAT1) with variation at a quantitative trait locus for milk fat content显示文摘 | Winter A Kramer W Werner F A at al | 2002 | Proc Natl Sci USA2002，99，14： | 1 |
| 18 | Development and validation of a HPLC method for the determination of sertraline and three non-chiral related impurities 显示文摘 | Ferrarini A Huidobro AL Pellati F | 2010 | J Pharm Biomed Anal2010，53，2： | 1 |
| 19 | llamh)mized prnspeclive Lrial enmparing immediale venus delayed ureteroseopy fnr patients with ureteral calculi anti normal renal function who present to the emer- gency department显示文摘 | Guercio S Ambu A Mangione F el al | 2011 | J Endourol2011，25，7： | 1 |
| 20 | Treatment with interferon-a2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques 显示文摘 | Falzarano D de Wit E Rasmussen AL Feldmann F Oku- mura A Scott DP Brining D Bushmaker T Martellaro C Baseler L Benecke AG Katze MG Munster VJ Feldma- nn H | 2013 | Nat Med2013，19，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员